Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial

医学 改良兰金量表 随机对照试验 闭塞 冲程(发动机) 不利影响 意向治疗分析 外科 内科学 缺血性中风 缺血 机械工程 工程类
作者
Xinfeng Liu,Qiliang Dai,Ruidong Ye,Wenjie Zi,Yuxiu Liu,Huaiming Wang,Wusheng Zhu,Minmin Ma,Qin Yin,Min Li,Xinying Fan,Wen Sun,Yunfei Han,Qiushi Lv,Rui Liu,Dong Yang,Zhonghua Shi,Dequan Zheng,Xiaorong Deng,Yue Wan
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:19 (2): 115-122 被引量:512
标识
DOI:10.1016/s1474-4422(19)30395-3
摘要

Background Previous randomised trials have shown an overwhelming benefit of mechanical thrombectomy for treating patients with stroke caused by large vessel occlusion of the anterior circulation. Whether endovascular treatment is beneficial for vertebrobasilar artery occlusion remains unknown. In this study, we aimed to investigate the safety and efficacy of endovascular treatment of acute strokes due to vertebrobasilar artery occlusion. Methods We did a multicentre, randomised, open-label trial, with blinded outcome assessment of thrombectomy in patients presenting within 8 h of vertebrobasilar occlusion at 28 centres in China. Patients were randomly assigned (1:1) to endovascular therapy plus standard medical therapy (intervention group) or standard medical therapy alone (control group). The randomisation sequence was computer-generated and stratified by participating centres. Allocation concealment was implemented by use of sealed envelopes. The primary outcome was a modified Rankin scale (mRS) score of 3 or lower (indicating ability to walk unassisted) at 90 days, assessed on an intention-to-treat basis. The primary safety outcome was mortality at 90 days. Secondary safety endpoints included the rates of symptomatic intracranial haemorrhage, device-related complications, and other severe adverse events. The BEST trial is registered with ClinicalTrials.gov, NCT02441556. Findings Between April 27, 2015, and Sept 27, 2017, we assessed 288 patients for eligibility. The trial was terminated early after 131 patients had been randomly assigned (66 patients to the intervention group and 65 to the control group) because of high crossover rate and poor recruitment. In the intention-to-treat analysis, there was no evidence of a difference in the proportion of participants with mRS 0–3 at 90 days according to treatment (28 [42%] of 66 patients in the intervention group vs 21 [32%] of 65 in the control group; adjusted odds ratio [OR] 1·74, 95% CI 0·81–3·74). Secondary prespecified analyses of the primary outcome, done to assess the effect of crossovers, showed higher rates of mRS 0–3 at 90 days in patients who actually received the intervention compared with those who received standard medical therapy alone in both per-protocol (28 [44%] of 63 patients with intervention vs 13 [25%] of 51 with standard therapy; adjusted OR 2·90, 95% CI 1·20–7·03) and as-treated (36 [47%] of 77 patients with intervention vs 13 [24%] of 54 with standard therapy; 3·02, 1·31–7·00) populations. The 90-day mortality was similar between groups (22 [33%] of 66 patients in the intervention vs 25 [38%] of 65 in the control group; p=0·54) despite a numerically higher prevalence of symptomatic intracranial haemorrhage in the intervention group. Interpretation There was no evidence of a difference in favourable outcomes of patients receiving endovascular therapy compared with those receiving standard medical therapy alone. Results might have been confounded by loss of equipoise over the course of the trial, resulting in poor adherence to the assigned study treatment and a reduced sample size due to the early termination of the study. Funding Jiangsu Provincial Special Program of Medical Science.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Jero完成签到 ,获得积分10
1秒前
3秒前
4秒前
海藻糖完成签到,获得积分10
4秒前
福蝶完成签到,获得积分10
6秒前
feng_qi001发布了新的文献求助10
8秒前
海藻糖发布了新的文献求助10
9秒前
李健应助如烈火如止水采纳,获得10
11秒前
Hayat发布了新的文献求助10
13秒前
feng_qi001完成签到,获得积分10
14秒前
16秒前
猕猴桃猴发布了新的文献求助10
16秒前
凤兮完成签到 ,获得积分10
17秒前
坤坤完成签到,获得积分10
18秒前
19秒前
20秒前
hh哈哈完成签到,获得积分10
21秒前
22秒前
番茄炒蛋发布了新的文献求助200
23秒前
RATHER发布了新的文献求助10
26秒前
小李完成签到 ,获得积分20
31秒前
31秒前
31秒前
加菲丰丰完成签到,获得积分0
34秒前
上官枫发布了新的文献求助10
36秒前
艾克发布了新的文献求助10
39秒前
猕猴桃猴完成签到,获得积分10
39秒前
LXinY完成签到 ,获得积分10
40秒前
40秒前
42秒前
春樹暮雲完成签到 ,获得积分10
43秒前
合适的语雪完成签到,获得积分10
44秒前
46秒前
上官枫完成签到,获得积分10
46秒前
哈哈发布了新的文献求助10
47秒前
47秒前
木马上市完成签到,获得积分10
51秒前
2019kyxb发布了新的文献求助10
53秒前
AAAADiao发布了新的文献求助10
53秒前
58秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 3000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
Maneuvering of a Damaged Navy Combatant 650
Mindfulness and Character Strengths: A Practitioner's Guide to MBSP 380
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3776482
求助须知:如何正确求助?哪些是违规求助? 3321990
关于积分的说明 10208326
捐赠科研通 3037279
什么是DOI,文献DOI怎么找? 1666628
邀请新用户注册赠送积分活动 797594
科研通“疑难数据库(出版商)”最低求助积分说明 757872